对帕金森病的非运动症状尺度的验证
Zahra Eghlidos1, Aida Abolhassanbeigi1, Zahra Rahimian1
1Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Parkinson's disease
|June 19, 2023
概括
波斯非运动症状尺度 (NMSS) 是评估伊朗帕金森病 (PD) 患者非运动症状的有效和可靠工具. 这项研究证实了它在这个人群中的准确性和一致性.
科学领域:
- 神经学 神经学
- 临床评估 临床评估
- 心理测量 心理测量 心理测量
背景情况:
- 非运动性症状对帕金森病患者的生活质量产生重大影响.
- 经过验证的工具对于准确评估不同人群中这些症状的负担至关重要.
- 非运动症状尺度 (NMSS) 是一个广泛用于此目的的仪器.
研究的目的:
- 评估NMSS的波斯语翻译的有效性和可靠性.
- 为了确定伊朗PD患者中波斯NMSS的心理测量特性.
- 为临床使用提供一个文化适应和验证的工具.
主要方法:
- 对波斯语的NMSS的跨文化适应.
- 一项涉及186名伊朗PD患者的横截面研究.
- 评估可接受性,可靠性 (克朗巴赫的α,测试重复测试) 和有效性 (与已建立的尺度如UPDRS,PDQ-8,BDI,SCOPA的相关性).
主要成果:
- 波斯语NMSS表现出卓越的测试重复测试可靠性 (总得分为0.93) 和内部一致性 (克朗巴赫的alpha0.84).
- 在波斯NMSS和相关尺度 (例如,UPDRS I,PDQ-8,BDI) 之间观察到很高的相关性,支持其融合有效性.
- 该尺度显示了基于疾病持续时间和严重程度的可接受的歧视性有效性.
结论:
- 波斯语版本的NMSS是一个有效和可靠的工具.
- 它准确地测量了伊朗帕金森病患者的非运动症状负担.
- 这种经过验证的工具可以帮助改善临床管理和研究.
相关概念视频
Parkinson's Disease: Overview
611
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
611
Parkinson's Disease: Treatment
303
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303


